e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Three years follow up after injection omalizumab therapy
D. Bhattacharyya (Delhi (New Delhi), India)
Source:
International Congress 2017 – Asthma management
Session:
Asthma management
Session type:
Thematic Poster
Number:
3974
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Bhattacharyya (Delhi (New Delhi), India). Three years follow up after injection omalizumab therapy. 3974
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Severe asthma outcomes over two years of therapy with mepolizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Outcomes over the first two years of treatment with mepolizumab in severe asthma
Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021
Year: 2021
The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old?
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
A comparison of nebulized budesonide, intramuscular and oral dexamethasone in the treatment of croup among children aged 6-36 months
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003
Does daily SMS increase adherence to asthma treatment? A three months follow-up study
Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches
Year: 2009
The effect of single dose inhaled budesonide on Amppc
20
in patients with mild asthma: a 3 month follow up
Source: Eur Respir J 2005; 26: Suppl. 49, 369s
Year: 2005
Growth deceleration of children on inhaled corticosteroids is compensated for after the first 12 months of treatment
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007
Asthma control and medication use five years after early or delayed introduction of inhaled corticosteroids in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
The success of CPAP therapy in patients over 70 years
Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects
Year: 2019
Six months and one year follow up of COPD patients who had oral nutritional supplement therapy as a part of pulmonary rehabilitation program
Source: Annual Congress 2012 - The latest insights in pulmonary rehabilitation
Year: 2012
Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Source: ERJ Open Res, 6 (3) 00068-2020; 10.1183/23120541.00068-2020
Year: 2020
The treatment with flunisolide in severe steroid asthmatics: the three-year follow-up study
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Long-term follow-up of patients under omalizumab initiated during the pre-approval period in France
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
The use of high-dose inhaled corticosteroids and add-on therapy in children in the UK: an observational study of 4332 patients
Source: Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Year: 2004
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 667s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept